Core Viewpoint - The internal speech by Zhao Yan, chairman of Huaxi Biological, highlights the urgent need for organizational reform and accountability within the company, amidst significant performance declines and internal turmoil [1][3][5]. Financial Performance - Huaxi Biological reported a revenue of 5.37 billion yuan for 2024, a year-on-year decrease of 11.6%, and a net profit of 164 million yuan, down 72.27% compared to the previous year [4][12]. - The company experienced a significant drop in its core functional skincare product revenue, which fell by over 18% for two consecutive years, with a 29.74% decline in the first half of 2024 [12][24]. Internal Challenges - The company has faced a high turnover of key technical personnel, with seven executives leaving in the past two years, including core technical staff [10][11]. - Zhao Yan's speech indicated a crisis within the organization, with terms like "problems" and "reform" frequently mentioned, reflecting the urgency of addressing internal management issues [5][6]. Strategic Shifts - Zhao Yan emphasized a return to a "start-up" mentality, focusing on operational aspects and addressing the need for a more agile and responsive organizational structure [5][21]. - The company is undergoing a significant internal restructuring, which has already cost over 270 million yuan, raising concerns about its financial health and future profitability [11][17]. Market Context - The broader pharmaceutical and biotechnology industry has seen a total market value decline of 14.3% in 2024, indicating a challenging environment for Huaxi Biological and its peers [20][21]. - The medical beauty industry, once characterized by high growth, is now facing a period of adjustment, with competitors also reporting declines in net profits [18][21]. Future Outlook - Zhao Yan expressed excitement and caution regarding the integration of AI in the life sciences sector, suggesting potential for significant changes in consumer engagement and decision-making processes [18][24]. - The company plans to introduce new talent and possibly restructure its core team to enhance its operational effectiveness and restore investor confidence [25].

对标胶原蛋白，具"爆品"潜质 据QYR预测，2023-2029年全球PDRN市场规模CAGR达到43.32%，其中中国地区CAGR可达到49%，虽然国内 PDRN行业已开始进入高速增长期，但由于原料本土化规模生产的问题才得到解决，以及终端市场目前还没有 大量的应用产品推出，当下市场规模仍然偏低。然而通过比对PDRN与胶原蛋白，我们认为中国PDRN市场， 随着原料本土规模化生产所带来的价格降低，以及护肤和医美领域的产品上市，其发展进度将远超预期。我们 认为PDRN将成为求美领域下一个"爆品"级赛道。 自研+资本，华熙系已成为PDRN的国家队 点击注册小程序 特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 报告摘要 PDRN——再生医学领域的"液体黄金" PDRN（多聚脱氧核糖核苷酸）是一种长度50-2000 bp、 ...

Investment Rating - The report maintains a "Recommended" investment rating for the industry [2] Core Views - Domestic demand remains a crucial driver for economic growth, with a positive outlook on leading consumer companies and a focus on AI+ consumption investment opportunities [2] - The Chinese government is expected to have more room for fiscal and monetary policy adjustments, which will further support domestic demand as a key growth driver [2] - As the economy gradually recovers and market expectations for stable growth policies increase, discretionary consumption is anticipated to see improvements in performance and valuation [2] Summary by Sections Industry Performance - The social service index fell by 2.82% from February 24 to February 28, 2025, ranking 25th among 31 industry indices [5] - The retail index increased by 1.55% during the same period, ranking 13th, with a cumulative increase of 8.15% since the beginning of 2024 [5] - The beauty care index rose by 1.67%, ranking 12th, but has seen a cumulative decline of 11.66% since the start of 2024 [5] Sub-Industry Dynamics Restaurant and Tourism - Greenland Group aims to achieve over 10 billion yuan in tourism revenue within five years [13] - Tongcheng Travel integrates AI technology to enhance user experience in travel solutions [13] Retail - The duty-free sector shows strong growth, with a significant increase in visitor numbers during the Spring Festival [16] - Major retail players like Yonghui Supermarket are expanding their presence through strategic partnerships [17] Beauty and Personal Care - The rise of private label brands is notable, with significant sales achievements in the cosmetics sector [19] - New product launches and technological advancements are driving growth in the beauty industry [20] Company Updates - Key companies in the social service sector, such as Kerui International, reported a revenue increase of 20.60% for 2024 [23] - Beijing Renli announced a strategic transfer of its subsidiary, reflecting ongoing adjustments in corporate structure [25] - Focus on digital transformation is evident in companies like Lianhua Supermarket, which raised funds for business ecosystem upgrades [18]

Investment Rating - The industry investment rating is "Outperform the Market" [2][22][29] Core Insights - The report highlights the record-breaking IPO of Mixue Ice City, which raised HKD 1.82 trillion, surpassing Kuaishou's previous record of HKD 1.26 trillion, with a subscription multiple of 5125 times [2][4] - During the 3.8 promotion event on Taobao and Tmall, domestic brands accounted for 41.7% of GMV, showing a year-on-year increase of 6.4% [2][6] - The report notes that the leisure service sector has shown resilience, with a year-to-date increase of 0.97% despite a decline in the broader market [2][19] Summary by Sections Industry Dynamics - Mixue Ice City's IPO set a new record with a subscription amount of HKD 1.82 trillion and a subscription multiple of 5125 times [2][4] - The 3.8 promotion event saw domestic brands contributing 41.7% to GMV, with a notable increase in the number of domestic brands in the top 20 [2][6] Company Updates - Beauty Industry - Babai Co. reported a revenue of CNY 695 million for 2024, up 48.24%, while Huaxi Bio's revenue decreased by 11.6% to CNY 5.371 billion [8] - Jinjian Bio achieved a revenue of CNY 1.447 billion, a growth of 85.4%, and a net profit increase of 144.65% [8] Company Updates - Travel Industry - Ctrip reported a total revenue of CNY 53.294 billion for 2024, a year-on-year increase of 19.73%, with a net profit of CNY 17.067 billion [10] - Huangshan Tourism is set to adjust its resource usage fees, which may reduce annual profits by approximately CNY 50 million during the trial period [10] Company Updates - Commercial Services and Retail - Core International achieved a revenue of CNY 11.793 billion, a growth of 20.6%, while Beijing Human Resources is restructuring to focus on its core business [12][10] Market Performance - The report notes that the Shanghai Composite Index fell by 1.72% during the week, while the leisure service sector saw a slight increase [19][23] - Key companies in the sector, such as Ctrip and Aimeike, experienced significant declines in stock prices, with Ctrip down 14.81% [19][21]

执业证书号：S1030523040001 电话：0755-23602217 邮箱：luopeng@csco.com.cn 大消费 [Table_ReportDate] 2025 年 3 月 3 日 [T分析师able_A：uthor 罗鹏 ] [Table_Industry] 研究助理：赵靖 电话：0755-23602217 邮箱：zhaojing2@csco.com.cn 公司具备证券投资咨询业务资格 证券研究报告 蜜雪冰城 IPO 融资认购额创港股历史纪录 [Table_ReportType] 大消费行业周报（2 月第 4 周） [Table_Summary] 行业观点： 风险提示：门店拓展不及预期、需求减弱、行业竞争加剧、宏 观经济增长放缓等风险。 请务必阅读文后重要声明及免责条款 [Table_Title] [Table_Report] [Table_BaseData] 计算机 2019 年 Q3 综合毛利率（%） 9.7 综合净利率（%） 6.9 行业 ROE（%） 25.6 行业 ROA（%） 5.2 利润增长率（%） 4.21 资产负债率（%） 149 期间费用率（%） 4.54 存货周转率（% ...

阿里市值现在又等于两个拼多多了。 受 AI 相关利好推动，年初至今阿里美股股价已上涨超 62 %，公司今日的市值（前一日收盘 3300 亿美元，27 日开盘后大约 3240 亿美元）约等于两个拼多多（前一日收盘 1663 亿美元，27 日开盘 后大约 1630 亿美元），五个京东（616 亿美元）。 国内电商的竞争格局没有大的变化，前三名分别是阿里、拼多多、抖音，京东稍有掉队降至第四 名。几家公司继续在它们擅长的品类上与淘天集团争夺份额，淘天则希望扶持优质品牌和商家在站 内站外做增长。在管理层宣布未来资本开支超过去十年总和后，资本市场此刻更愿意把阿里视作一 家 AI 公司，而非传统电商零售公司。 阿里的电商对手们对 AI 的态度不一，抖音电商希望增加用户覆盖和直播电商规模，增加搜索产生 的 GMV ，暂未提及如何用 AI ；京东两年前就开发了大模型言犀 AI，此刻更多关注美团，想在外 卖和即时零售赛场上与美团开战。 苹果官方旗舰店接入国补，比拼多多更便宜。 继华为、小米、OPPO 等四十多家国内外手机品牌官方下场参与国补后，苹果近期也调整策略，其 线上天猫官方店铺已接入北京国补，售价 6000 元以内的多款产 ...

Financial Performance - Total revenue for 2024 was RMB 5,370,823,906.35, a decrease of 11.60% compared to the previous year[3] - Net profit attributable to shareholders was RMB 164,315,939.59, down 72.27% year-on-year[3] - The company reported a significant decline in net profit excluding non-recurring gains and losses, amounting to RMB 101,220,042.48, a drop of 79.36%[3] Assets and Equity - Total assets at the end of the reporting period were RMB 8,630,976,709.76, reflecting a 1.90% increase from the beginning of the period[4] - Shareholder equity decreased by 2.00% to RMB 6,805,043,213.48 compared to the beginning of the period[4] Business Challenges and Strategic Adjustments - The company faced challenges in its functional skincare business due to intensified market competition and strategic adjustments, with ongoing adjustments expected to continue[5] - Management transformation costs exceeded RMB 70 million, impacting short-term profitability but aimed at long-term growth[6] - A significant impairment provision of approximately RMB 190 million was made for accounts receivable, inventory, and goodwill due to identified impairment risks[7] Strategic Investments and Future Growth - Strategic investments in innovative business areas, including regenerative medicine and functional foods, exceeded RMB 100 million, targeting future growth opportunities[6] - The company is undergoing a strategic upgrade focusing on synthetic biology and aims to enhance operational efficiency and achieve high-quality growth[8]

Financial Performance - The company expects a net profit attributable to shareholders of RMB 146 million to RMB 175 million for 2024, a decrease of RMB 417.56 million to RMB 446.56 million, representing a year-on-year decline of 70.47% to 75.36%[2] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is RMB 80 million to RMB 109 million, a decrease of RMB 381.48 million to RMB 410.48 million, representing a year-on-year decline of 77.78% to 83.69%[2] - The previous year's net profit attributable to shareholders was RMB 592.56 million, with a total profit of RMB 701.72 million[3] - The company has experienced a decrease in government subsidies directly impacting current profits compared to the previous year[9] Business Development - The company has maintained steady growth in its raw material business, benefiting from localized operations in international markets, leading to sustained sales growth in Europe, Japan, and the Americas[5] - The company launched two new medical aesthetic injection products under its brand, which are expected to enhance its product line and market presence[5] - The company has increased strategic investments in emerging business areas such as regenerative medicine and functional foods, with over RMB 100 million allocated to innovation initiatives[6] Management and Strategy - Management transformation initiatives have incurred costs exceeding RMB 70 million, impacting short-term profitability but laying a foundation for long-term growth[5] - The company is undergoing a strategic upgrade focused on high-quality growth and operational efficiency improvements, which may create greater long-term development space despite short-term pressures[8] Impairment and Provisions - A significant impairment provision of approximately RMB 210 million has been made for accounts receivable, inventory, and goodwill due to impairment indications[6]

暴利行业持续分化洗牌。 作者 | 贝壳XY 编辑 | 小白 正所谓，爱美之心，人皆有之。如今，美容护理已越发融入人们的日常生活中，其市场需求持续扩 大。国家统计局数据显示，我国化妆品类零售总额在过去二十多年里呈现稳步提升，2023年达到4,14 2亿元，较2011年增长接近3倍。 但2024年1-11月的情况却有些不同，化妆品类零售总额罕见出现负增长，同比下滑了1.3%，莫非化妆 品生意不好做了？ （来源：Choice终端，制表：市值风云APP） 这组数据背后，其实意味着两层含义，其一是化妆品需求的小幅减少，其二则是行业内卷越发严重。 消费需求越发向头部品牌集中，质量不佳、规模较小、生产不良的尾部企业正逐渐被淘汰出局，一场 席卷整个行业的大洗牌或许正在进行。 动荡过后，仍能留在牌桌上的企业必定各有各的看家本领，今天我们便从美容护理板块前十大市值公 司来一探究竟。 参考申万行业分类及截至2024年12月31日的市值排名，前十大公司分别为爱美客（300896.SZ）、珀 莱雅（603605.SH）、华熙生物（688363.SH）、稳健医疗（300888.SZ）、锦波生物（832982.BJ）、 贝泰妮（30095 ...

Financial Performance - The company's operating revenue for Q3 2024 was ¥1,064,002,047.03, representing a decrease of 7.14% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was ¥20,258,275.61, down 77.44% year-on-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥10,583,321.09, a decrease of 85.37% compared to the previous year[2]. - The net cash flow from operating activities for Q3 2024 was ¥9,433,742.96, down 80.53% year-on-year[2]. - The basic earnings per share for Q3 2024 was ¥0.04, a decrease of 78.95% compared to the same period last year[3]. - Total operating revenue for the first three quarters of 2024 was approximately ¥3.87 billion, a decrease of 8.2% compared to ¥4.22 billion in the same period of 2023[14]. - Net profit for the first three quarters of 2024 was approximately ¥359 million, down 29.2% from ¥507 million in the same period of 2023[15]. - Operating profit for the first three quarters of 2024 was approximately ¥436 million, a decrease of 28.6% compared to ¥611 million in the same period of 2023[15]. - The basic earnings per share for the first three quarters of 2024 were ¥0.75, down from ¥1.07 in the same period of 2023[16]. Research and Development - The total R&D investment for Q3 2024 was ¥112,579,760.38, an increase of 24.52% year-on-year, accounting for 10.58% of operating revenue[3]. - Research and development expenses for the first three quarters of 2024 were approximately ¥313 million, an increase of 13.0% compared to ¥277 million in the same period of 2023[14]. Assets and Liabilities - The total assets at the end of the reporting period were ¥8,687,961,992.22, an increase of 2.57% compared to the end of the previous year[3]. - As of September 30, 2024, the total assets of the company amounted to RMB 8,687,961,992.22, an increase from RMB 8,470,008,293.83 at the end of 2023, reflecting a growth of approximately 2.58%[12]. - The company's total current liabilities decreased to RMB 1,136,227,866.53 from RMB 1,220,791,687.05, a reduction of approximately 6.9%[13]. - Total liabilities as of the end of the third quarter of 2024 were approximately ¥1.63 billion, an increase of 9.9% from ¥1.49 billion at the end of the third quarter of 2023[14]. - The company's total non-current assets reached RMB 6,005,480,452.74, up from RMB 5,347,153,037.58, reflecting an increase of about 12.2%[13]. Shareholder Information - The company reported a total of 32,273 common shareholders at the end of the reporting period[7]. - The largest shareholder, Huaxi Xinyu Investment Co., Ltd., held 58.86% of the shares[7]. - The company did not report any significant changes in the top 10 shareholders or their participation in margin trading activities during the reporting period[12]. Cash Flow - Cash flow from operating activities for the first three quarters of 2024 was approximately ¥4.18 billion, a decrease of 10.7% compared to ¥4.68 billion in the same period of 2023[17]. - Cash outflow from investment activities totaled approximately 953.74 million, a decrease from 1.85 billion in the previous period[19]. - Net cash flow from investment activities was negative at approximately -306.09 million, compared to -378.60 million last year[19]. - Cash inflow from financing activities was 100 million, an increase from 51.72 million in the previous period[19]. - Cash outflow from financing activities totaled approximately 449.70 million, slightly down from 465.54 million last year[19]. - Net cash flow from financing activities was negative at -349.70 million, compared to -413.83 million in the previous period[19]. - The ending balance of cash and cash equivalents was approximately 434.81 million, a decrease from 692.96 million in the previous period[19]. - The company's cash and cash equivalents decreased to RMB 511,521,498.37 from RMB 1,168,717,886.67, indicating a decline of about 56.3%[12]. Other Information - The company has adopted new accounting standards starting in 2024, which may affect financial reporting[20].